AstraZeneca has appointed Laura Colón as the new president of AstraZeneca Spain to lead the company's strategy in one of the group's most important markets globally. Her mission will focus on driving scientific development, accelerating the delivery of new treatments to patients, and consolidating AstraZeneca's contribution to the healthcare system and the scientific and economic fabric, strengthening Spain's role as a priority location within the company's global growth strategy.

In addition to this role, Laura Colón will be the Site Leader of the AstraZeneca Global Hub in Barcelona, which has established itself as a driving force for biomedical, digital, and commercial innovation in Europe. This international center represents a new innovation model that combines biomedicine, data science, digital innovation, and commercial excellence. The Hub currently has more than 1,600 employees and is making a decisive contribution to AstraZeneca's global goal of making 20 new medicines available to patients before the end of the decade.

Since December 2023, Laura Colón has led AstraZeneca's Oncology division in Spain, driving cutting-edge research in one of the company's most active scientific areas. During this time, she has worked closely with the entire healthcare system and played a key role in introducing new treatments and expanding therapeutic indications, enabling more patients to benefit from advances in areas with significant unmet needs, such as liver, breast, and lung cancer, as well as hematological malignancies. This work has been recognized by AstraZeneca's Oncology division as the company with the best reputation in this specialty in 2025, achieving first place in the Merco Healthcare Reputation Monitor (MRS).

Laura Colón has over 20 years of experience in the pharmaceutical industry, having held senior management positions in Spain and internationally. She joined AstraZeneca in 2019 as Head of the Lung Cancer Franchise, and in 2021 moved to Singapore to assume the role of International Director of the Lung, Gastrointestinal, Genitourinary, and Gynecological Cancer franchises. Previously, she worked at companies such as Roche, Biogen, and AbbVie. She holds a degree in Psychology from the Autonomous University of Madrid and has completed executive training in Business, Strategy, and Innovation.